10x Genomics vs Vizgen, Inc.
10x Genomics holds the stronger position because it already has the revenue base and market lead that Vizgen is being squeezed by, including a patent settlement working in 10x's favor.
10x Genomics
Makes single-cell and spatial genomics instruments and consumables used in biology labs worldwide
Vizgen, Inc.
Vizgen makes MERSCOPE, a spatial transcriptomics platform using MERFISH imaging chemistry
Dimension by dimension
| Dimension | 10x Genomics | Vizgen, Inc. |
|---|---|---|
| Staying power of the core product | 10x Genomics generates hundreds of millions in yearly revenue from instruments and consumables used across biology labs. | Vizgen sells spatial mapping hardware and chemistry but has disclosed no revenue, relying on repeated funding rounds to keep operating. |
| Exposure to AI absorbing the product | Rated unlikely to be absorbed by AI. | Rated unlikely to be absorbed by AI. |
| How easily a giant could copy them | Rated only possible for a larger player to copy. | Rated likely to be copied by a larger player. |
| Pressure from rivals | Faces no named rival taking share; pressure instead comes from customers delaying purchases ahead of 10x's own Atera launch and NIH funding cuts. | Faces direct pressure from 10x Genomics' dominant Xenium platform and a patent settlement that likely brings royalty payments. |
| Financial footing | Posted $598.7M in FY2025 revenue excluding settlement funds, with FY2026 guidance of $600-625M and $150.8M in Q1 2026 revenue. | Has raised over $250M cumulatively including a fresh $48M round in January 2026, with over 100 employees to support. |
| Overall standing | Described as defensible for now. | Described as losing its protection. |
Questions people ask
- Vizgen vs 10x Genomics, who is under more competitive pressure?
- Vizgen is under more direct pressure, facing the dominant Xenium platform from 10x Genomics itself plus a patent settlement that likely means ongoing royalty payments. 10x Genomics is not confirmed to be losing share to any named rival; its pressure comes from customers waiting on its own new Atera product and from NIH funding cuts.
- Which company has stronger revenue, Vizgen or 10x Genomics?
- 10x Genomics reported $598.7M in FY2025 revenue excluding settlement funds and guided to $600-625M for FY2026. Vizgen has not disclosed revenue figures, only cumulative funding raised of over $250M.
- Is Vizgen or 10x Genomics easier for a big tech company to copy?
- Vizgen is rated likely to be copied by a larger player, while 10x Genomics is rated only possible. That gives 10x Genomics a somewhat more defensible position.
- Are Vizgen and 10x Genomics at risk from AI replacing their products?
- Neither company is seen as likely to have its product absorbed by AI. Both make physical lab instruments and chemistry that AI does not directly substitute.
- What is the main risk each company faces right now?
- Vizgen's main risk is the patent settlement and royalty terms tied to 10x Genomics' dominant Xenium platform. 10x Genomics' main risk is customers pausing purchases ahead of its own Atera launch combined with reduced NIH funding.
Other comparisons with these companies